Retifanlimab is the first immunotherapy specifically approved for advanced anal cancer, offering a new treatment option for eligible NHS patients
iStock
This Site is Intended for Healthcare Professionals Only
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Start your day right!
Get the latest updates and insights delivered to your inbox
Only just over a quarter of eligible young people have received the first dose of MenB
iDtock
Older people and those with underlying health conditions are among the groups most vulnerable to the effects of cold weather
iStock
The Access to Medicine Foundation says the growing commercial focus on weight-loss drugs could leave millions of people in lower-income countries short of some medication
iStock
×
Terms and Conditions
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Asian Trade
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at
data@amg.biz
to see how we manage and store your data.
×
Terms and Conditions
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Asian Trade
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.